Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $49.11 Average Price Target from Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has been assigned an average rating of “Buy” from the thirteen research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $49.1111.

A number of brokerages have recently weighed in on STRO. Mizuho set a $50.00 price target on shares of Sutro Biopharma and gave the stock an “outperform” rating in a report on Thursday, April 30th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Sutro Biopharma from $51.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Citizens Jmp upped their price target on shares of Sutro Biopharma from $35.00 to $41.00 and gave the stock a “market outperform” rating in a report on Thursday, April 23rd. Wells Fargo & Company raised shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $8.00 to $27.00 in a report on Tuesday, March 24th. Finally, HC Wainwright upped their price target on shares of Sutro Biopharma from $28.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, May 15th.

Sutro Biopharma Stock Down 9.0%

NASDAQ STRO opened at $26.09 on Monday. The company has a market capitalization of $432.31 million, a P/E ratio of -2.36 and a beta of 1.54. Sutro Biopharma has a 12-month low of $6.74 and a 12-month high of $43.85. The firm has a 50-day moving average price of $30.81 and a two-hundred day moving average price of $20.26.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($2.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The firm had revenue of $14.52 million for the quarter, compared to the consensus estimate of $8.89 million. Equities analysts expect that Sutro Biopharma will post -9.29 EPS for the current year.

Institutional Trading of Sutro Biopharma

A number of institutional investors and hedge funds have recently made changes to their positions in the company. State of Tennessee Department of Treasury bought a new position in Sutro Biopharma in the 4th quarter valued at approximately $86,000. Sigma Planning Corp bought a new position in Sutro Biopharma in the 1st quarter valued at approximately $312,000. Bank of America Corp DE lifted its stake in Sutro Biopharma by 348.1% in the 1st quarter. Bank of America Corp DE now owns 18,873 shares of the company’s stock valued at $470,000 after purchasing an additional 14,661 shares during the last quarter. Jane Street Group LLC bought a new position in Sutro Biopharma in the 4th quarter valued at approximately $265,000. Finally, Stempoint Capital LP bought a new position in Sutro Biopharma in the 1st quarter valued at approximately $580,000. Institutional investors own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.